COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D HC QHC Q Vitamin CV.C ZincZn PVP-IPVP-I FLVFLV REGNR2 LY-CoVLY RemdesivirRMD
HCQ study #136 of 255
9/12 Late treatment study
Heberto et al., IJC Heart & Vasculature, doi:10.1016/j.ijcha.2020.100638 (Peer Reviewed)
Implications of myocardial injury in Mexican hospitalized patients with coronavirus disease 2019 (COVID-19)
Source   PDF   Share   Tweet
Observational prospective 254 hospitalized patients, HCQ+AZ mortality odds ratio OR 0.36, p = 0.04.
Ventilation OR 0.20, p = 0.008.

Heberto et al., 9/12/2020, prospective, Mexico, North America, peer-reviewed, 8 authors.
risk of death, 53.6% lower, RR 0.46, p = 0.04, treatment 139, control 115, odds ratio converted to relative risk.
risk of ventilation, 65.6% lower, RR 0.34, p = 0.008, odds ratio converted to relative risk.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. For an individual study the most serious outcome may have a smaller number of events and lower statistical signficance, however this provides the strongest evidence for the most serious outcomes when combining the results of many trials.
Details of all 255 studies    Meta analysis
Please send us corrections, updates, or comments.